ENXTPA:SANPharmaceuticals
Sanofi Pipeline Milestones Sharpen Focus On Specialty Growth Potential
Sanofi received FDA Breakthrough Therapy designation for oral venglustat targeting neurological symptoms in type 3 Gaucher disease.
Sanofi reported positive phase 3 results for amlitelimab in atopic dermatitis.
European regulators issued a positive opinion for Sarclisa subcutaneous with an on body injector for multiple myeloma, potentially introducing dual administration modes in the EU.
Sanofi, traded as ENXTPA:SAN, is currently priced at €81.99 and has seen a 5.4% gain over the past week,...